Eurocor Tech - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Eurocor presented 12 months outcomes of Spanish Registry on the occasion of EuroPCR in Paris

Date: 2011/05/18

• During the Symposium (Drug-eluting balloons: current practice and future perspectives) sponsored with an unrestricted Grant from Eurocor, the 12 month FU results of the Spanish multicenter registry were presented by the Principal Investigator Dr. Antonio Serra
• International Symposium dedicated to experiences with drug-eluting balloons (DEB)

Paris, May 18, 2011 – On the occasion of EuroPCR Dr. Antonio Serra (Spain) announced the 12 months outcomes of the Spanish multicenter registry in Paris during the international Eurocor Symposium on March 17, 2011. The study was conducted to investigate the outcome after DIOR® drug-eluting balloon (DEB) treatment of in-stent restenosis (ISR) lesions. All ISR were investigating bare metal stent ISR as well as drug- eluting stent ISR. A second focus of that study was the treatment of small vessels, a challenging subset of patients where treatment options are currently limited. 250 patients were enrolled in 10 Spanish centers. The results at 12 months follow up show a low target lesion revascularization (TLR) rate of 9.2% in BMS-ISR and 14.8% in DES-ISR. In very small vessels (1.98 mm mean vessel diameter) the TLR rate at 12 months was very low with 2.9%, what is remarkable. This shows that the treatment of coronary in-stent restenosis with the paclitaxel-eluting balloon DIOR® provides good immediate and mid- term outcomes. The manuscript on the subset of patients with ISR lesions has been accepted for publication recently.

During the well visited symposium Prof. Silber (Germany) provided a lecture on the current role of DEBs. He pointed out, that the DIOR DEB is according to the ESC guidelines (2010) IIa, which recommends that DEB can be used for ISR in BMS. Dr. Pieter Stella (Netherlands) then presented the database of the Valentines Trial with the largest group of patients ever enrolled to show efficacy of DEB in treatment of ISR. The studies show that the DIOR® (DEB) is safe and effective in treatment of in-stent restenosis (ISR).

Prof. Schulte from Germany highlighted a glimpse of first experiences with the drug- eluting peripheral PT A Balloon FREEW A YTM and announced first results of new randomizes studies. Dr. Chandra from India, Dr. Alfredo Rodriguez from Argentina and Prof. Huay Cheem Tan from Singapore rounded the international view on innovative drug-eluting balloon technologies and experiences with high class products such as DIOR® DEB and FREEWAYTM DEB.

Eurocor Spanish Registry Outcomes